TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29178760

Group type: EXPERIMENTAL
Intervention: Toothpaste containing lysozyme
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified what control was used)
Number of subjects: 70
Study: 24737786

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 487

Group type: COMPARATOR
Intervention: Conventional treatment (sulfasalazine+hydroxychloroquine)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Infliximab vs Conventional treatment
Number of subjects: 487
Study: 22633663

Group type: EXPERIMENTAL
Intervention: Distal protection and thrombus aspiration (DP-TA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional PCI (c-PCI)
Number of subjects: 126
Study: 21590485

Group type: EXPERIMENTAL
Intervention: Operative treatment (primary fixation)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 95
Study: 18430574

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Number of subjects: 392

Group type: COMPARATOR
Intervention: Sodium Hyaluronate
Number of subjects: 392
Study: 16847589

Group type: EXPERIMENTAL
Intervention: Model Development (MD) group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Model Validation (MV) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Other models tested
Number of subjects: 40
Study: 16163534

Group type: EXPERIMENTAL
Intervention: Acute tyrosine and phenylalanine depletion (TPD)
Number of subjects: 14
Study: 12514655

Group type: EXPERIMENTAL
Intervention: Coumarin group (aspirin plus coumarins started 1 week before the procedure)
Number of subjects: 531

Group type: COMPARATOR
Intervention: ASA group (aspirin alone)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Optimal anticoagulation (defined as an international normalized ratio >70% of the follow‐up time in the target range)
Number of subjects: 531
Study: 10362332

Group type: EXPERIMENTAL
Intervention: Oral glutamine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 134
Study: 8847042

Group type: EXPERIMENTAL
Intervention: Interferon (6 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prednisone plus Interferon (6 months)
Number of subjects: 19
Study: 2286796

Group type: EXPERIMENTAL
Intervention: Pelvic regional hyperthermia (HT) using BSD‐1000 HT system and annular phased array (AA) applicator or BSD‐2000 HT system and Sigma‐60 (S60) applicator
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pelvic regional hyperthermia (HT)
Number of subjects: 26
Study: 6270708

Group type: EXPERIMENTAL
Intervention: ACTH4-10 (Org O163) 30 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ACTH4-9 analog (Org 2766) dosages of 0.05 mg, 0.5 mg, and 5 mg
Number of subjects: 20
Study: 29679899

Group type: EXPERIMENTAL
Intervention: Parents of VLBW infants
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group (parents of term infants)
Number of subjects: 403
Study: 27846471

Group type: EXPERIMENTAL
Intervention: Training program consisting of 72 sessions over 9 months
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 152
Study: 25377872

Group type: EXPERIMENTAL
Intervention: GSK1278863 (300 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK1278863 (15 mg daily for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22695408

Group type: EXPERIMENTAL
Intervention: Cachexia defined by Cancer Cachexia Study Group (CCSG)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cachexia defined by CCSG
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Nutritional risk
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cachexia
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sarcopenia (low muscle mass)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: No nutritional risk, malnutrition, or cachexia
Number of subjects: 77
Study: 21087072

Group type: EXPERIMENTAL
Intervention: Targeted age-specific computerized alert
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control clinics without alert
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control clinics after alert activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention clinics after alert activation
Number of subjects: 0
Study: 18679152

Group type: EXPERIMENTAL
Intervention: HIV-1-infected mothers
Number of subjects: 2623

Group type: COMPARATOR
Intervention: HIV-1-uninfected mothers
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Infants of HIV-1-infected mothers
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Infants with early HIV-1 infection (birth to 4-6 weeks)
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Maternal factors (HIV-1-infected mothers)
Number of subjects: 2623
Study: 17136941

Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) diet (GI: 70)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) diet (GI: 35)
Number of subjects: 7
Study: 12895690

Group type: EXPERIMENTAL
Intervention: Soya supplement (60 mg total isoflavone equivalents/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10905487

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8811149

Group type: EXPERIMENTAL
Intervention: 3-mL syringe
Number of subjects: 29

Group type: COMPARATOR
Intervention: 1-mL syringe
Number of subjects: 29
Study: 1577222

Group type: EXPERIMENTAL
Intervention: Once-a-day morning administration of 40 mg famotidine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Once-a-day bedtime administration of 40 mg famotidine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Both treatments (morning and bedtime famotidine)
Number of subjects: 99
Study: 3919579

Group type: EXPERIMENTAL
Intervention: Oral and parenteral antibiotic prophylaxis
Number of subjects: 86

Group type: COMPARATOR
Intervention: Parenteral antibiotic prophylaxis
Number of subjects: 86
Study: 31444404

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (untreated women)
Number of subjects: 87
Study: 29725951

Group type: EXPERIMENTAL
Intervention: High-perspective-taking manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-perspective-taking manipulation
Number of subjects: 0
Study: 25690541

Group type: EXPERIMENTAL
Intervention: Green tea dentifrice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluoride-triclosan dentifrice
Number of subjects: 30
Study: 24957482

Group type: EXPERIMENTAL
Intervention: Functional Status-II (FS-II) independence scores at 18 months
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Impact on Family (IOF) scales
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: General health (GH) scores at 18 months
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Functional Status-II (FS-II) independence scores association with disability
Number of subjects: 111
Study: 22607736

Group type: EXPERIMENTAL
Intervention: Higher total estradiol levels
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Higher free estradiol levels
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lower testosterone to estradiol ratio
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lower total testosterone levels
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lower testosterone/estradiol ratio
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lower free testosterone levels
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Higher testosterone/estradiol ratio
Number of subjects: 148
Study: 20881341

Group type: EXPERIMENTAL
Intervention: SCTG plus EMD
Number of subjects: 12

Group type: COMPARATOR
Intervention: SCTG only
Number of subjects: 12
Study: 19020142

Group type: EXPERIMENTAL
Intervention: Open sigmoidectomy with sevoflurane anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic sigmoidectomy with sevoflurane anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open sigmoidectomy with propofol anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoidectomy with propofol anesthesia
Number of subjects: 0
Study: 16095427

Group type: EXPERIMENTAL
Intervention: Moderate-volume group (MVG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-volume group (LVG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: High-volume group (HVG)
Number of subjects: 51
Study: 12895219

Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaris 1 g three times daily for 6 months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaris 2 g three times daily for 6 months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaris 3 g three times daily for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10695778

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 0
Study: 7587186

Group type: EXPERIMENTAL
Intervention: Low-dose oral triphasic contraceptives
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 2030054

Group type: EXPERIMENTAL
Intervention: Exercise at intensities ranging from 50‐80% VO2max
Number of subjects: 19

Group type: COMPARATOR
Intervention: Exercise intensity expressed as %VO2max
Number of subjects: 19

Group type: COMPARATOR
Intervention: Exercise intensity expressed as %OBLA
Number of subjects: 19
Study: 6184023

Group type: EXPERIMENTAL
Intervention: 5% albumin (Group 1, 27 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: hetastarch (Group 2, 33 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% albumin (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: hetastarch (Group 2)
Number of subjects: 60
Study: 31318132

Group type: EXPERIMENTAL
Intervention: Internet-based peer support groups (ISGs)
Number of subjects: 183
Study: 29543887

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously once every 6 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alendronate (35 mg orally once a week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of Denosumab vs Alendronate
Number of subjects: 32
Study: 26917355

Group type: EXPERIMENTAL
Intervention: Distal bulbar double-cuff (DC) insertion
Number of subjects: 180

Group type: COMPARATOR
Intervention: Proximal bulbar single-cuff (SC) insertion
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall device explantation
Number of subjects: 180
Study: 23114725

Group type: EXPERIMENTAL
Intervention: Secretagogues
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metformin only (Control)
Number of subjects: 20
Study: 21823103

Group type: EXPERIMENTAL
Intervention: Biofield healing
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mock healing
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Belief
Number of subjects: 76
Study: 20216324

Group type: EXPERIMENTAL
Intervention: Gender-tailored cardiac rehabilitation program
Number of subjects: 252

Group type: COMPARATOR
Intervention: Traditional outpatient cardiac rehabilitation program
Number of subjects: 252
Study: 17439564

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236

Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236
Study: 15616290

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate at 2,000/125 mg (5 days)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate at 875/125 mg (7 days)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 893
Study: 12151148

Group type: EXPERIMENTAL
Intervention: Preeclampsia group (40 women)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normotensive control group (31 women)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Severe preeclampsia group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nulliparous women with preeclampsia
Number of subjects: 71
Study: 10669900

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 8915932

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIG) 750 mg/kg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIG)
Number of subjects: 17
Study: 1872270

Group type: EXPERIMENTAL
Intervention: Urokinase (1,000,000 U intravenous bolus dose), followed by heparin infusion 3 hours later
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Heparin (10,000 U intravenous bolus, followed by continuous infusion)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional therapy only (intravenous nitroglycerin, beta blockers and calcium antagonists)
Number of subjects: 43
Study: 6358552

Group type: EXPERIMENTAL
Intervention: Self-care education program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse counseling session added to written materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone information service
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-care education systems
Number of subjects: 0
Study: 31684759

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (1.5 µg/min for 20 minutes)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 34
Study: 28748706

Group type: EXPERIMENTAL
Intervention: Sensor-integrated pump system with a low glucose threshold suspend feature (SIP+TS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard metrics of hypoglycemia
Number of subjects: 0
Study: 25588971

Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fibre group
Number of subjects: 47
Study: 25074387

Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT) 20 g
Number of subjects: 17

Group type: COMPARATOR
Intervention: Long Chain Triglycerides (LCT) 20 g (corn oil)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT)
Number of subjects: 17
Study: 22736340

Group type: EXPERIMENTAL
Intervention: General inhalational anesthesia (GA group, n = 30)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA group, n = 28)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia plus sedation with midazolam (SA+S group, n = 29)
Number of subjects: 87

Group type: COMPARATOR
Intervention: General inhalational anesthesia (GA group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Spinal anesthesia plus sedation with midazolam (SA+S group)
Number of subjects: 87
Study: 20015490

Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management (Control)
Number of subjects: 0
Study: 17514424

Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclipping
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Oral proton pump inhibitors (PPIs)
Number of subjects: 129
Study: 16318813

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 100-120 mg BCG plus 100 mg para-aminomethyl benzoic acid (PAMBA)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 50-60 mg BCG plus 100 mg PAMBA
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 100-120 mg BCG plus 2.0 g epsilon-aminocaproic acid (EACA)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 50-60 mg BCG plus 2.0 g EACA
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group: 100-120 mg BCG
Number of subjects: 326
Study: 11942864

Group type: EXPERIMENTAL
Intervention: Albumin 40 g/L (7.1 mL/kg, i.e. 500 mL per 70 kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextran 30 g/L (7.1 mL/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ringer's acetate (21.4 mL/kg)
Number of subjects: 12
Study: 11435045

Group type: EXPERIMENTAL
Intervention: Upper body surface warmer with abducted upper extremities (n=19)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: No upper body surface warmer with abducted upper extremities (n=19)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No upper body surface warmer with adducted upper extremities (n=10)
Number of subjects: 48
Study: 9739798

Group type: EXPERIMENTAL
Intervention: Encoding strategy before consuming the prepared meal
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Recognition replaced free recall
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Encoding strategy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no encoding strategy)
Number of subjects: 94
Study: 8069885

Group type: COMPARATOR
Intervention: 0 ppm F from sodium fluoride dentifrice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 250 ppm F from sodium fluoride dentifrice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1,000 ppm F from sodium fluoride dentifrice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exclusion of data from 1 low-caries subject
Number of subjects: 12
Study: 2657276

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 235837

Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg body weight)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg body weight) + Bromazepam (0.1 mg/kg body weight) - subjects kept awake
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg body weight) + Bromazepam (0.1 mg/kg body weight) - subjects allowed to sleep
Number of subjects: 5

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 5
Study: 372292

Group type: EXPERIMENTAL
Intervention: Nylidrin hydrochloride (24 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31714970

Group type: EXPERIMENTAL
Intervention: High Positive End-Expiratory Pressure (PEEP) with recruitment maneuvers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low PEEP
Number of subjects: 0
Study: 29370333

Group type: EXPERIMENTAL
Intervention: Consensus definition of orthostatic hypotension (OH)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Clinical HR definition of orthostatic hypotension
Number of subjects: 1094
Study: 25939484

Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo-adalimumab
Number of subjects: 180
Study: 24307620

Group type: EXPERIMENTAL
Intervention: ICG fluorescence
Number of subjects: 68

Group type: COMPARATOR
Intervention: Blue dye
Number of subjects: 68
Study: 22343798

Group type: EXPERIMENTAL
Intervention: Intravenous NAC
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Intrarenal NAC
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 20840176

Group type: EXPERIMENTAL
Intervention: Coping group intervention
Number of subjects: 247

Group type: COMPARATOR
Intervention: Support group (control)
Number of subjects: 247
Study: 17040589

Group type: EXPERIMENTAL
Intervention: Co-phenylcaine administered for 10 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Co-phenylcaine administered for 1 minute
Number of subjects: 50
Study: 16131292

Group type: EXPERIMENTAL
Intervention: Static magnet device (2700 gauss)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo device (140 gauss)
Number of subjects: 65
Study: 11831546

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin coadministered with 2 mg everolimus
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin coadministered with 2 mg everolimus
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2 mg everolimus alone
Number of subjects: 24
Study: 10086532

Group type: EXPERIMENTAL
Intervention: Axial blood flow pump (Hemopump; HP) as circulatory support
Number of subjects: 32

Group type: COMPARATOR
Intervention: CPB, aortic cross-clamping, and cardioplegic arrest
Number of subjects: 32
Study: 8748680

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (S-T)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (other neurological diseases)
Number of subjects: 8
Study: 1923103

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (Ara-C) 100 mg/m2 12 hourly for seven days and daunorubicin (DNR) 45 mg/m2 daily for three days followed by three further courses of Ara-C (five days) and DNR (two days) in the same dosage.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Three courses of VP16 100 mg/m2 daily for five days and one dose of mAMSA of 200 mg/m2 as postremission consolidation.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall treatment protocol.
Number of subjects: 92
Study: 7462667

Group type: EXPERIMENTAL
Intervention: UVA + UVB irradiation
Number of subjects: 8

Group type: COMPARATOR
Intervention: UVB irradiation
Number of subjects: 8
Study: 31566129

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 32
Study: 30585454

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (ginger-separated snake moxibustion), 3 cones per session, once a week for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control A group (no specific intervention mentioned)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control A group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control B group (normal subjects)
Number of subjects: 90
Study: 27179849

Group type: EXPERIMENTAL
Intervention: Endobronchial coils treatment (n=158)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Usual care (n=157)
Number of subjects: 315
Study: 24383406

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment of Insomnia (BBTI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Information Control (IC)
Number of subjects: 30
Study: 22103435

Group type: EXPERIMENTAL
Intervention: 1% nadifloxacin combined with topical anti-acne products (adapalene, benzoyl peroxide, azelaic acid, isotretinoin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical anti-acne products (adapalene, benzoyl peroxide, azelaic acid, isotretinoin) alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated control area
Number of subjects: 40